26th July - 26th July 2012 | Online
Category: R&D
Address: Online
Organiser: The Jackson Laboratory
Website: CLICK HERE to open.
Webinar: Modeling Human Malignancy with Patient-Derived Xenograft Cancer Models
Wednesday, July 26, 1:00 PM (ET in US)
Patient-derived xenograft (PDX) cancer models show great promise as preclinical models because they reflect the diversity of human cancers seen in the clinic. The Jackson Laboratory’s PDX program was developed in collaboration with renowned cancer hospitals to advance the course of preclinical drug development. Join our technical information scientists Drs. Andrew Schile and Sheri Kuslak-Meyer and
• Learn how more than 100 “all comers” PDX models have been established in partnership with a consortium of cancer hospitals and clinical trial teams
• Appreciate how the diversity of the PDX program represents current patient demographics
• See how the genetics, pathology, and treatment response of PDX tumors reflect clinical observations
• Understand how patient-derived hematological cancers are modeled in the mouse
• Learn about current advances that take advantage of the immunodeficient NSG mouse host
• Understand how to access PDX models through JAX In Vivo Pharmacology Services
Register for this free webinar today at www.jax.org/jaxmice/news/2012/pdxWebinarJuly
Source:
0 comments:
Post a Comment